![]() |
|||||||||||||
|
All | Since 2019 | |
Citation | 5450 | 3969 |
h-index | 23 | 20 |
i10-index | 134 | 84 |
DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR ESTIMATION OF ANTI ARTHRITIS/ ANTI PSORIASIS DRUG IN PHARMACEUTICAL DOSAGE FORM
Ankita Vikram Kengar*, Dr. Prachi P. Udapurkar and Dr. Lahu D. Hingane
ABSTRACT
Apremilast (Otezla) drug is administrated by oral root and it is phosphodiesterase 4 inhibitor, now approved with significant amounts of adverse effect, newer treatment options with an efficacious outcome, sans the toxicity, is something all clinicians would implement readily in their therapeutic regimens. Apremilast is one such drug which has shown promise in the management of psoriasis, PsA, and a few other dermatologic disorders. This review will throw light on the dermatologic prespective regarding apremilast. Apremilast is used for treatment of psoriasis and psoriatic arthritis. It may also be beneficial for other inflammayor diseases relevant to the immnune system. Keywords: Apremilast, Phosphodiesterase 4 inhibitor, psoriasis, psoroatic arthropathy. [Download Article] [Download Certifiate] |